1. Home
  2. ACRV vs PLCE Comparison

ACRV vs PLCE Comparison

Compare ACRV & PLCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.08

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Logo Children's Place Inc. (The)

PLCE

Children's Place Inc. (The)

HOLD

Current Price

$2.12

Market Cap

62.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRV
PLCE
Founded
2018
1969
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
74.0M
62.0M
IPO Year
2022
1997

Fundamental Metrics

Financial Performance
Metric
ACRV
PLCE
Price
$2.08
$2.12
Analyst Decision
Buy
Hold
Analyst Count
4
1
Target Price
★ $11.67
$3.50
AVG Volume (30 Days)
★ 295.2K
252.8K
Earning Date
05-08-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 15.13
11.48
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$568.17
$4.41
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.27
$1.82
52 Week High
$3.56
$9.56

Technical Indicators

Market Signals
Indicator
ACRV
PLCE
Relative Strength Index (RSI) 54.90 41.79
Support Level $2.07 $2.04
Resistance Level $2.21 $2.88
Average True Range (ATR) 0.13 0.17
MACD 0.01 -0.00
Stochastic Oscillator 73.68 41.55

Price Performance

Historical Comparison
ACRV
PLCE

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

About PLCE Children's Place Inc. (The)

Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.

Share on Social Networks: